This article is more than 5 years old. Information may no longer be current.
VIDEO: Expert discusses results from HOPE-3 trial
Click Here to Manage Email Alerts
CHICAGO — In this video exclusive, George Bakris, MD, offers insight on the HOPE-3 study, a large international trial that evaluated the effect on CV events of statins and combination BP therapy with an angiotensin receptor-blocker and a low-dose diuretic, at the American College of Cardiology Scientific Session.
According to the results, in the overall cohort, statin use with 10mg of rosuvastatin showed a clear benefit in the reduction of CV events, but BP control did not.
“However, there was a subgroup of people with a mean [BP] of a little over 143 [mm Hg], and that group did show benefit,” said Bakris, professor of medicine and director of ASH comprehensive hypertension center at University of Chicago Medicine, and a member of the Cardiology Today Editorial Board.
Bakris also considers whether there should be a polypill approach using statin and BP-lowering therapy.
According to Bakris, “It is very clear that even people with early stage I hypertension do get a benefit in terms of reducing CV risk. Regardless of cholesterol levels at baseline … the bottom line is, you do get a benefit, especially on ischemic events related to MI, stroke, etc.”